Osteogenesis Imperfecta Treatment Market, By Drugs (Teriparatide, Denosumab, and Others) By Route of Administration (Subcutaneous, Intravenous, Oral, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Osteogenesis imperfect, or OI, is a genetic disorder that affects the bones and also prevents the body from building strong bones. This disease makes the bones brittle and breaks easily without any cause. OI is referred to as imperfect bone formation, and people suffering from this disorder have bones that fracture or break easily. Therefore, this condition is also commonly known as brittle bone disease. In severe OI cases, multiple fractures are common, whereas a milder case involves a few fractures or bone breaks in a person's lifetime. People with this condition are either born unable to produce connective tissue or have it due to faulty genes. It has an impact on the synthesis of collagen, the connective tissue protein that strengthens bones. The illness comes in I and IX forms, with I being mild and IX being fatal. The major sign of osteogenesis imperfecta is frequent fractures. Other symptoms include loose joints, deformed bones, loss of hearing, breathing issues, and tooth problems. Osteogenesis imperfecta can be confirmed through DNA or collagen testing. There is no treatment for it because it is a genetic condition. Exercise and giving up smoking are two examples of healthy lifestyle choices that can help prevent fractures. Braces, painkillers, and correct bone fracture care are all beneficial. Antibiotics and antiseptics can be used to treat bone infections. Rising demand for novel therapies for osteogenesis imperfecta treatment and licensing agreements and strategic collaborations by key industry players for the development of OI treatment are expected to propel the growth of global osteogenesis imperfecta treatment market over the forecast period.
Market Dynamics
The surge in funding for research & development to develop novel treatment and therapies is a major factor boosting growth of the global osteogenesis imperfecta treatment market. Moreover, licensing agreements and strategic collaborations by key industry players for the development of OI treatment is another factor propelling the market growth. Moreover, osteogenesis imperfecta is a genetic disorder and the family history of people with OI is resulting in rising number of cases across the globe, which is expected to drive the market growth. For instance, in May 2021, Mereo BioPharma Group plc announced encouraging 6-month data from its phase II-B clinical study in adult patients with Type IV, III, or I osteogenesis imperfecta treated with setursumab (BPS-804). The European Medicines Agency (EMA) had approved the company’s pediatric investigation plan for BPS-804 and with a registration study design, and the drug candidate is now phase III ready for a pediatric population.
Key features of the study:
This report provides in-depth analysis of the global osteogenesis imperfecta treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global osteogenesis imperfecta treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global osteogenesis imperfecta treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteogenesis imperfecta treatment market
Detailed Segmentation:
Global Osteogenesis Imperfecta Treatment Market, By Drugs:
Teriparatide
Denosumab
Others
Global Osteogenesis Imperfecta Treatment Market, By Route of Administration:
Subcutaneous
Intravenous
Oral
Others
Global Osteogenesis Imperfecta Treatment Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
BioSenic SA
Mereo Biopharma Group PLC
CELGENE CORPORATION
Eli Lilly and Company
Cipla Inc.
Amgen Inc.
Sun Pharmaceutical Industries Ltd.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Jubilant Pharmova Limited
Aurobindo Pharma
Quince
Ultragenyx Pharmaceutical Inc.
OrthoPediatrics Corp.
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Drugs
Market Snapshot, By Route of Administration
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
New Development in Osteogenesis Imperfecta Treatment
Pipeline Analysis
Merger, Acquisition, Collaborations
Funding and Investment
Key Developments
PEST Analysis
PORTER’s Analysis
4. Global Osteogenesis Imperfecta Treatment Market– COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Osteogenesis Imperfecta Treatment Market, By Drugs, 2018-2030, (US$ Million)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018-2030
Segment Trends
Teriparatide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Denosumab
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
6. Global Osteogenesis Imperfecta Treatment Market, By Route of Administration, 2018-2030, (US$ Million)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018-2030
Segments Trends
Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
7. Global Osteogenesis Imperfecta Treatment Market, By Region, 2018-2030, (US$ Million)
Introduction
Market Share Analysis, By Region, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Region, 2018–2030
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Million)
North Africa
Central Africa
South Africa
8. Competitive Landscape
BioSenic SA
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Mereo Biopharma Group PLC
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
CELGENE CORPORATION
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Amgen Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Sun Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Viatris Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Jubilant Pharmova Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Aurobindo Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Quince
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Ultragenyx Pharmaceutical Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
OrthoPediatrics Corp.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
9. Section
Research Methodology
About Us
*Browse 32 market data tables and 25 figures on “Osteogenesis Imperfecta Treatment Market”- Global forecast to 2030